HIL – Human Insight Israel, Israel

Registration Status: Completed

Objective: Human Insight Israel (HIL) is an Israel Innovation Authority–funded national biobank capturing clinical and large-scale proteomic data at the Emergency Department timepoint, across three Israeli hospitals. The program is led by MeMed Diagnostics and aims to enroll 10,000 patients stepwise by clinical domain (2,000 per domain), starting with acute infectious diseases. Plasma samples undergo deep proteomic profiling, paired with harmonized clinical data. HIL is designed to lower the barrier to early-stage proteomic discovery in acute care, a setting under-represented in existing biobank infrastructure.

Registered Biobank Name	HIL – Human Insight Israel
Biobank Leader	Eran Reiner, MD
Country	Israel
Email for biobank inquiries	eran.reiner@me-med.com
Principal Investigator	Eran Reiner, MD
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).